Treatment implications of the latent reservoir for HIV-1. (Q36857114)

16 August 2017

1 reference

title

Treatment implications of the latent reservoir for HIV-1. (English)

1 reference

16 August 2017

4

Robert F Siliciano

1 reference

16 August 2017

Susan Peterson

1

1 reference

PubMed ID

17586322

16 August 2017

Alison P Reid

series ordinal

2

1 reference

PubMed ID

17586322

16 August 2017

Scott Kim

series ordinal

3

1 reference

16 August 2017

1 January 2007

1 reference

16 August 2017

Advances in Pharmacology

1 reference

16 August 2017

55

1 reference

16 August 2017

411-425

1 reference

Anti-HIV therapy: Current and future directions

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Molecular Characterization, Reactivation, and Depletion of Latent HIV

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Latent reservoirs of HIV: obstacles to the eradication of virus

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

1 reference

7 January 2021

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

The latent reservoir for HIV-1 in resting CD4+ T cells and other viral reservoirs during chronic infection: insights from treatment and treatment-interruption trials

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

HIV and lymphocyte dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

The emergence and characterization of macrophage-tropic SIV/HIV chimeric viruses (SHIVs) present in CD4+ T cell-depleted rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

The multifactorial nature of HIV-1 latency

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Depletion of latent HIV-1 infection in vivo: a proof-of-concept study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Decay characteristics of HIV-1-infected compartments during combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Latency in human immunodeficiency virus type 1 infection: no easy answers

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

A long-term latent reservoir for HIV-1: discovery and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Stability of the latent reservoir for HIV-1 in patients receiving valproic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Hypersusceptibility to substrate analogs conferred by mutations in human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2807%2955012-X

7 January 2021

10.1016/S1054-3589(07)55012-X

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17586322